Mergers And Acquisitions

Achelous Partners specializes in Mergers and Acquisitions and related corporate advisory assignments including:

  • Sell-Side Mandates
  • Buy-Side Mandates
  • Valuation Modeling
  • Fairness Opinions
  • Mergers of public and private companies
  • Takeover Defense
  • Schemes of Arrangement
  • Tender and Exchange offers
  • Restructurings, Divestitures and Spin-offs
  • Leveraged Buyouts and Private Equity Investments
  • Strategic Investments and Joint Ventures
Our Competence
  • Our bankers provide high quality senior-level advice and expertise to the Boards of our corporate clients
  • We specialize in the healthcare, life science, biotech and pharma industry sectors, allowing us to provide insight and shape a strategy that is most relevant to those sectors
  • We have the right combination of diverse backgrounds in investment banking, capital markets, legal, life science industry and academia, to be able to manage the most complex cross-border transactions
  • We fulfill our clients’ desire for objective independent advice
  • We assist our clients to originate and execute assignments, no matter how complex
  • We transact across the entire spectrum of deal size
Our Independence
  • Not only are we independent but we are perceived to be independent
  • We are specialist corporate advisors free to operate without the pressure to cross-sell other products and services
  • We are not partial to the size of deals, our only incentive is to push for the best deal in order for us to earn our client's trust on the next assignment
Our Difference
  • Our bankers spend significant time meeting clients and potential M&A opportunities across North America, Europe, Australia, Asia and Latin America
  • We service clients globally with our own office in New York and through relentless traveling
  • We bring a global perspective combined with local knowledge and technical expertise
  • We provide a broader choice of targets and acquirors
  • We have significant expertise in structuring cross-border deals which provide value added outcomes for our clients’ shareholders
  • We advise a broad range of small, medium and large public and private enterprises around the globe
How We Work
  • Our bankers spend significant time and energy getting to know our clients’ businesses and understanding their strategic objectives
  • We are results/solutions driven
  • We provide and maintain absolute client confidentiality
  • We provide the highest quality independent advice to our clients’ Boards
  • We are acutely aware of the importance of management and cultural fit
  • We focus on efficient deal execution
  • We strive to create shareholder value for our clients
  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
Top